Both ibrutinib (Imbruvica) and venetoclax (Venclexta) carry an approved indication for use in chronic lymphocytic leukemia but do not often lead to complete remission, and therapy routinely continues indefinitely or until disease progression.
Jennifer Salvon
Advertisement
Articles by Jennifer Salvon
Lenvima (lenvatinib) is approved for the treatment of thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma.
Tirzepatide is a dual receptor agonist, acting on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 to lower blood glucose levels.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Cyclosporiasis Cases Reach 5100: Investigators Zero In On Lettuce, Possible Taco Bell Link
2
Subcutaneous Olanzapine in Schizophrenia: Expanding the Utility of a Proven Therapy
3
Patient-Reported Outcomes, Machine Learning May Predict Breast Cancer Recurrence Earlier
4
Psychedelics in Cluster Headaches Are Breaking the Pain Cycle
5